Collaborative and Other Relationships (Tables)

12 Months Ended

Dec. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Our share of annual co-promotion profits in excess of $50.0 million varies, as summarized in the table below, upon the following events:



Until GAZYVA First Non-CLL FDA Approval	40.0	%
After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date	39.0	%
After First GAZYVA Threshold Date until Second GAZYVA Threshold Date	37.5	%
After Second GAZYVA Threshold Date	35.0	%

First Non-CLL GAZYVA FDA Approval means the FDA’s first approval of GAZYVA in an indication other than CLL.

First GAZYVA Threshold Date means the earlier of (i) the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12-month period were at least $150.0 million or (ii) the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $150.0 million.

Second GAZYVA Threshold Date means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $500.0 million. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.

Pretax profit sharing formula

Our share of annual profits in excess of $50.0 million varies, as summarized in the table below, upon the following events:



Until First GAZYVA Threshold Date	39.0	%
After First GAZYVA Threshold Date until Second GAZYVA Threshold Date	37.5	%
After Second GAZYVA Threshold Date	35.0	%

Revenues from anti-CD20 therapeutic programs

Revenues from anti-CD20 therapeutic programs are summarized as follows:



	For the Years Ended December 31,
(In millions)	2017		2016		2015
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses	$	1,316.4	$	1,249.5	$	1,269.8
Other revenues from anti-CD20 therapeutic programs	242.8		65.0		69.4
Total revenues from anti-CD20 therapeutic programs	$	1,559.2	$	1,314.5	$	1,339.2

Summary of activity related to collaboration with AbbVie Inc.

The following table provides a summary of the U.S. collaboration and our share of the co-promotion losses on ZINBRYTA in the U.S.:



	For the Year Ended December 31,
(In millions)	2017		2016
Product revenues, net	$	53.1	$	6.1
Costs and expenses	92.6		50.0
Co-promotion losses in the U.S.	$	39.5	$	43.9
Biogen's share of co-promotion losses in the U.S.	$	16.9	$	21.9

Summary of activity related to collaboration with Eisai

A summary of activity related to the Eisai Collaboration Agreement is as follows:



	For the Years Ended December 31,
(In millions)	2017		2016		2015
Total development expense incurred by the collaboration in development of BAN2401 and E2609	$	146.2	$	95.1	$	84.1
Biogen's share of BAN2401 and E2609 development expense reflected in our consolidated statements of income, excluding upfront and milestone payments	$	74.3	$	50.5	$	40.4